Navigation Links
Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
Date:5/23/2013

MENLO PARK, Calif., May 23, 2013 /PRNewswire/ -- Virobay, Inc. today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor.  

The first Phase 1 trial of VBY-036 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of VBY-036 in healthy adults.

"The initiation of this Phase 1 trial with VBY-036 represents another significant development objective for Virobay," stated Robert Booth , Ph.D., Chief Executive Officer of Virobay.  "Published preclinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with a variety of painful disorders, including neuropathic pain.  In addition, research carried out by Virobay with selective cathepsin S inhibitors has demonstrated efficacy in preclinical models of both acute and chronic inflammatory pain and neuropathic pain," stated Robert Booth .  "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-036.  To the best of our knowledge, VBY-036 is first-in-class with this therapeutic approach for the treatment of pain."

"Reaching this important milestone brings us one step closer to providing a new treatment for patients suffering with painful conditions.  Virobay is committed to providing novel therapies for unmet medical needs and strives to constantly expand and improve treatment options for patients.  Virobay also initiated clinical studies with VBY-891, a selective cathepsin inhibitor in March of this year.  VBY-891 is being developed in partnership with LEO Pharma for the
'/>"/>

SOURCE Virobay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. Applied Genetics Initiates Commercial Operation
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Clara, California (PRWEB) March 03, 2015 ... development service company, has launched a new Life Science ... reagents for preclinical research. , The first products ... antibody isotype controls, and soon to be released in ... company will continue to expand their life science portfolio ...
(Date:3/3/2015)... -- Fried, Frank, Harris, Shriver & Jacobson LLP announced ... the Firm as a partner in the Intellectual Property ... office. Mr. Lewis concentrates on patent litigation ... intellectual property and general litigation. A trained chemical engineer ... and defendants in a range of technology-related sectors but ...
(Date:3/3/2015)... HubCast® Inc. ( http://www.hubcast.com ), the leader ... of its Global Print Supply Chain with next-day delivery ... largest cities across 75 countries globally. The HubCast ... global enterprises ease, speed, reach, quality, cost savings and ... to real-world delivery at postal address around the globe. ...
(Date:3/3/2015)... -- Thingee Corporation, a software development company for the Life ... Adoption: Making Reps, Lives Easier" during the 2015 Synergistix ...  in Deerfield Beach, Florida , taking ... to learn how technology can help them do their ... audience for the Thingee presentation. ...
Breaking Biology Technology:Crown Bioscience Launches Life Science Product Catalog 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Thingee to present at 11th Annual Synergistix Users Conference 2
... 27 ReGear Life Sciences, Inc. announced today that ... cleared ReBound™ Diathermy System to Life Care Centers of ... therapeutic heating system that improves quality of life by ... injury, aging and disease.   Ease of ...
... Quarter Fiscal 2010 -- LAIYANG, China, Sept. 27 /PRNewswire-Asia-FirstCall/ -- ... ... --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Cellectis bioresearch, the specialist in genome customization and subsidiary ... launch of its e-store, with approximately one hundred ready-to-use ... and intuitive website. Launched in 2008, Cellectis ... integration kits, which offer a simple, effective means of ...
Cached Biology Technology:ReGear Life Sciences Partners with Life Care Centers of America 2Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 2Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 3Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 4Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 5Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 6Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 7Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store 2Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store 3
(Date:3/2/2015)... 2015   Neurotechnology , a provider of high-precision ... SentiGaze Software Development Kit (SDK). The SentiGaze algorithm ... off-the-shelf webcams to track eye movements and generate heatmaps ... Heatmaps can be used for applications such as analysis ... The SDK can also be used to develop interfaces ...
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... of craggy peaks, the highesta mountain known as Noshaqhas ... duty in this mountainous terrain must often ascend to ... climbs without adapting to altitude can lead to a ... fatigue, gastrointestinal distress, nausea, and insomnia. Conventional knowledge ...
... account for over half of vertebrate species, but while groups ... understood by scientists for decades, knowledge about relationships among many ... A team of scientists led by Richard Broughton, ... Sciences at the University of Oklahoma, published two studies that ...
... have revealed how a bacterial enzyme has evolved an ... findings, published in Science , present further insight ... a class of enzymes called helicases, a widely-distributed group ... some cancers. The new helicase mechanism discovered in ...
Cached Biology News:2 days of staging as effective as 4 for high-altitude climbs 22 days of staging as effective as 4 for high-altitude climbs 3Something's fishy in the tree of life 2Random walks on DNA 2
...
Griess Reagent component for determination of nitrite in aqueous solutions....
... terminators, template DNA, primers, salts or other ... have proved critical for both standard and ... work with dye terminator cycle sequencing chemistries ... unique uniformity of the magnetic paeticles guarantees ...
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
Biology Products: